Table 1.
Baseline characteristics of all randomized participants
| Variable | Curcumin, n=34 | Placebo, n=34 |
|---|---|---|
| Age, yr | 18±6 | 19±5 |
| Sex, women, n (%) | 19 (56%) | 18 (53%) |
| Race and ethnicity, n (%) | ||
| Non-Hispanic White | 28 (82%) | 28 (82%) |
| Hispanic or other | 6 (14%) | 6 (18%) |
| eGFR, ml/min per 1.73 m2 | 115±16 | 118±19 |
| BMI category | ||
| Normal weight or underweight | 23 (68%) | 24 (71%) |
| Overweight | 6 (18%) | 8 (24%) |
| Obese | 5 (15%) | 2 (6%) |
| Systolic BP, mm Hg | 116±12 | 118±19 |
| Diastolic BP, mm Hg | 71±9 | 73±10 |
| Hypertension | 13 (38%) | 16 (47%) |
| Medications, n (%) | ||
| ACEi/ARB | 9 (27%) | 12 (35%) |
| Any antihypertensive | 10 (29%) | 13 (3%) |
| Statin | 5 (15%) | 7 (21%) |
| Oral contraceptive or IUDa | 7 (21%) | 4 (12%) |
| Psychiatric medications | 5 (15%) | 3 (9%) |
| Mayo classification, n (%) b | ||
| 1A | 0 (0%) | 4 (12%) |
| 1B | 2 (6%) | 5 (15%) |
| 1C | 7 (21%) | 2 (6%) |
| 1D | 9 (27%) | 6 (18%) |
| 1E | 7 (21%) | 10 (29%) |
| Not applicable | 9 (27%) | 7 (21%) |
Data are mean ± SD or percentage. eGFR is by the full age spectrum equation. BP was the mean office reading in the seated position. BMI, body mass index; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; IUD, intrauterine device.
a
Percentage of women.
b
Mayo classification is only applicable in participants ≥15 years of age (n=44). Those in the not applicable category were <15 years of age.